John Pedersen named Chairman of the Board – DYSIS Medical

John Pedersen named Chairman of the Board

John Pedersen named Chairman of the Board

John Pedersen named Chairman of the Board at DYSIS Medical


ALPHARETTA, Georgia — February 6, 2020 — DYSIS Medical today announced that John Pedersen has assumed the position of Board Chairman.  Pedersen most recently served as CEO of Augmenix, a privately held company that manufactured and sold minimally invasive hydrogel products to improve outcomes following cancer radiotherapy. Augmenix was sold to Boston Scientific in 2018 for $600M.


Prior to joining Augmenix, Pedersen served as a Senior Healthcare Advisor for two healthcare private equity funds – The Gores Group and The Pritzker Group. In addition, he served on the Boards of Directors of two medical device companies – Clinical Innovations and Therakos. Prior to this, Pedersen was President of the Urology and Women’s Health Division at Boston Scientific.


“I’m looking forward to working closely with our CEO Darin Hammers and the other board members to continue moving this organization forward,” Pedersen said. “It’s an exciting time to be a part of DYSIS as we continue to expand the company and bring our advanced cervical imaging technology to clinicians worldwide.”


Pedersen earned an MBA from The Harvard Graduate School of Business Administration and an AB degree from Princeton University.


“We are excited to have John join our board as we work to make our innovative DYSIS Ultra device the standard of care for colposcopy.  He brings a tremendous amount of leadership experience in the medical device field and a proven track record of commercial success,” said Casper Breum of Lundbeckfondon Ventures.


About DYSIS Medical

DYSIS Medical Inc. is based in Alpharetta, Georgia. The Company is committed to early detection and diagnosis of cervical disease using biophotonic innovations. DYSIS is committed to becoming the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit



Brent Palmisano